⌕
Cytokinetics · CYTK · Nasdaq
Tenet 34 · Weak
Compare
$51.65−2.86%At closeTenet 34 · Weak
$51.65−1.52 (−2.86%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Cytokinetics (CYTK) Stock

Cytokinetics (CYTK) closed at $51.65 on Nov 17, 2026; its Tenet Score is 34 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

38 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$51.65
Nov 17, 2026
Market cap
$7.4B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
52.68 – 88.31
low → high · as of close, Nov 16, 2026
Tenet Score
34/100
Weak · 340 Healthcare peers

Industry: Drugs

Cytokinetics Inc scores 34/100. Weak. Growth is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 34 is built from 3 of 4 pillars, from 45% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=340
34/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
24
Health
56
Growth
21

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value omitted — no data yet.
Value—QualityFHealthCGrowthFMomentumD
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
65.4×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
−695.4%
fiscal 2025, before interest and tax
Net margin
−686.6%
TTM through Sep 30, 2026
Current ratio
3.36
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidat…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 131 US ETFs · top wrappers by weightSee all ETFs holding CYTK →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Cytokinetics in?

Cytokinetics is in the Healthcare sector and the Drugs industry.

What is Cytokinetics' Tenet Score?

Cytokinetics' Tenet Score is 34 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.